Jim Wright, MD

Trials

Studies that name Jim Wright, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:40 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06421675 · Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

  Ontario Clinical Oncology Group (OCOG) · recruiting · Refractory Multiple Myeloma · study director
• Ph2
  NCT05137899 · Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy

  Ontario Clinical Oncology Group (OCOG) · terminated · Hepatocellular Carcinoma, Portal Vein Tumour Thrombosis · study director
• Ph2
  NCT00391248 · Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

  Ontario Clinical Oncology Group (OCOG) · completed · Non-small Cell Lung Cancer · principal investigator
• Ph3
  NCT00310232 · Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

  Ontario Clinical Oncology Group (OCOG) · terminated · Non-Small-Cell Lung Carcinoma, Lung Cancer, Anemia · study chair
• Ph2
  NCT00230191 · Safety and Efficacy of RK0202 in Oral Mucositis

  RxKinetix · completed · Mouth Diseases, Mouth Ulcers, Oral Mucositis · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.